Skip to main content
. 2016 Feb 20;7(12):14569–14585. doi: 10.18632/oncotarget.7538

Figure 6. MiR-410 functioned by targeting SLC34A2 through Wnt/β-catenin pathway in NSCLC cells.

Figure 6

(A and B) Western blotting analysis of β-catenin, DVL2 and Gsk3β protein expression in A549 A. and 95D B. cells after transfecting with miR-410 inhibitors/NC or mimics/NC. Overexpression of miR-410 significantly up-regulated DVL2 and β-catenin respectively, and down-regulated Gsk3β, while inhibition of miR-410 down-regulated DVL2 and β-catenin respectively, and up-regulated Gsk3β in both A549 A. and 95D B. cells compared with their respective control. (C and D) Western blotting analysis of β-catenin, DVL2 and Gsk3β protein expression in A549 C. and 95D D. cells after cotransfecting with p3.1-SLC34A2/p3.1 or siRNA-SLC34A2/siRNA-NC. Overexpression of SLC34A2 significantly down-regulated DVL2 and β-catenin respectively, and up-regulated Gsk3β, while inhibition of SLC34A2 up-regulated DVL2 and β-catenin respectively, and down-regulated Gsk3β in both A549 C. and 95D D. cells compared with their respective control. (E and F) Western blotting analysis of β-catenin, DVL2 and Gsk3β protein expression in A549 E. and 95D F. cells after cotransfecting with miR-410 inhibitors and siRNA-SLC34A2. Down-regulation of DVL2 and β-catenin, and up-regulation of Gsk3β were partly impaired in both A549 E. and 95D F. cells after cotransfecting with miR-410 inhibitors/NC and siRNA-SLC34A2 compared with that of cells transfecting with miR-410 inhibitors/NC. *, p < 0.05; **, p < 0.01, significant difference vs NC control.